Target intelligence / Profile preview

Hepatitis B virus major surface antigen (HBsAg)

Target
HBsAg
Molecular classification
Viral protein, Envelope protein, Antigen
01

Overview

Hepatitis B virus major surface antigen (HBsAg) is a key envelope glycoprotein found on the surface of the hepatitis B virus (HBV) and is the primary serological marker used to diagnose acute and chronic HBV infections. HBsAg plays a critical role in the viral life cycle, facilitating viral attachment and entry into host hepatocytes by interacting with the sodium taurocholate co-transporting polypeptide (NTCP) receptor. In chronic HBV infection, the virus produces and secretes vast quantities of non-infectious subviral particles composed of HBsAg, which act as an immunological decoy to exhaust and suppress the host's immune response, preventing viral clearance. Consequently, reducing HBsAg levels is considered a prerequisite for achieving a 'functional cure,' defined as sustained undetectable HBV DNA and HBsAg loss after stopping therapy. Therapeutic strategies targeting HBsAg include antisense oligonucleotides (such as the FDA-approved bepirovirsen) and small interfering RNAs (siRNAs like elebsiran and xalnesiran) that degrade viral transcripts to suppress HBsAg production. Additionally, monoclonal antibodies (such as tobevibart) and hepatitis B immune globulins directly bind and neutralize circulating HBsAg, blocking viral entry and promoting immune-mediated clearance of viral particles.

Other names
HBsAgHepatitis B surface antigenHepatitis B virus surface antigenLarge envelope proteinLHBL-HBsAgS proteinMajor surface antigenAustralia antigen
02

Mechanism of action

Antisense oligonucleotides (e.g., bepirovirsen) and small interfering RNAs (siRNAs; e.g., elebsiran, xalnesiran) target and degrade HBV RNA transcripts to inhibit HBsAg translation. Monoclonal antibodies (e.g., tobevibart) and immune globulins directly bind to the antigenic loop of HBsAg, neutralizing viral infectivity, blocking NTCP-mediated entry into hepatocytes, and promoting clearance of viral particles. Nucleic acid polymers (e.g., REP 2139) prevent the assembly and secretion of HBsAg-containing subviral particles.

03

Biological functions

Viral entryViral attachmentHost-virus interactionEndocytosisMembrane fusion
04

Disease associations

InfectionHepatitis BHepatitis DHepatocellular carcinomaCirrhosis
05

Safety considerations

On-treatment hepatic flares (severe ALT elevations)Thrombocytopenia (sudden decline in platelet counts)Injection site reactionsWorsening renal functionSevere HBV exacerbation or viral relapse after treatment discontinuationSerious inflammatory or immune-mediated reactions
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

Serum HBsAg levelsHBV DNA levelsAlanine aminotransferase levelsPlatelet countAnti-HBs antibody titers

Beyond the preview

Go deeper on Hepatitis B virus major surface antigen (HBsAg).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus major surface antigen (HBsAg).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call